Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-005 in Severe COVID-19
NCT04748757Phase 2Completed
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of annexin a5 in coronavirus disease 2019 (COVID-19) and sepsis (3 arms). Primary endpoints: Enrollment at 12 months, Protocol adherence at 7 days and 1 more. Started Apr 2021; status: completed.
02
Drugs
annexin a5
03
Conditions
coronavirus disease 2019 (COVID-19)sepsis
Beyond the preview
Go deeper on NCT04748757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748757.